Abstract. Luteolin, a common dietary flavonoid, induces the apoptosis of cells in several types of cancer. However, its role in myelodysplastic syndrome (MDS) and the potential underlying mechanisms remain to be elucidated. To evaluate the potential benefit and underlying mechanisms of luteolin in MDS cells, the viability of SKM-1 cells and primary bone marrow (PBM) mononuclear cells from patients with intermediate- or high-risk MDS were assessed using a cell counting Kit-8 assay. The apoptotic features of cell morphology were assessed using Wright-Giemsa staining, DNA fragmentation was analyzed by agarose gel electrophoresis, and the extent of apoptosis was quantified by flow cytometry (FCM). Reactive oxygen species (ROS) were measured by FCM with 2,7-dichlorodihydrofluorescein diacetate staining and mitochondrial membrane potential ($\Delta\Psi_m$) was determined using 5,5',6,6'-tetrachloro-1',3',3'-tetraethylbenzimidazolylcarbocyanine iodide staining. Caspase activity was detected using a fluorometric protease assay. Furthermore, the effects of luteolin on the expression of apoptosis-related proteins were analyzed using western blot analysis. The resulting data revealed that luteolin significantly inhibited the proliferation of SKM-1 cells in vitro, and its half maximal inhibitory concentration was 139.41 µM at 24 h and 23.95 µM at 72 h. Luteolin also markedly inhibited the proliferation of mononuclear cells from patients with intermediate- or high-risk MDS. Luteolin suppressed cell proliferation, mainly as a result of the induction of apoptosis, as demonstrated by typical apoptotic morphological features, the ladder pattern of genomic DNA fragmentation, and the results of FCM using Annexin V-FITC/PI double staining. It was also found that short-term exposure of SKM-1 cells to luteolin led to a marked increase in the accumulation of ROS. The increased intracellular level of ROS appeared to induce the activation of p53 and elevate the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, which modulates $\Delta\Psi_m$ and triggers the release of cytochrome c, and may increase the activities of apoptotic protease activating factor 1, caspase-3, -8 and -9 to further trigger the destruction of structural and specific proteins and thereby cell apoptosis. Notably, the inhibition of ROS generation by the antioxidant N-acetyl-L-cysteine significantly attenuated the luteolin-induced loss of $\Delta\Psi_m$ and activities of caspase-3, -8 and -9. These data suggested that luteolin exerts its pro-apoptotic action partly through the p53-dependent mitochondrial signaling pathway mediated by intracellular ROS, which provides a promising therapeutic candidate for patients with MDS.

Introduction

Myelodysplastic syndromes (MDS) are a group of related clonal stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenia and an increased risk of progression to acute myeloid leukemia (1). Despite aggressive treatments, patients >60 years of age, or with secondary or therapy-related acute myeloid leukemia have the poorest prognosis, and those with high-risk MDS ineligible for allogeneic stem cell transplantation have similar outcomes, predominantly due to high rates of relapse (2). As previous studies have shown that only 5-15% of patients with therapy-related myelodysplasia or myeloid leukemia show long-term survival (3), the identification of novel effective agents with more benign toxicity profiles is required to improve the survival rate of patients with MDS. Natural dietary compounds obtained from fruits, vegetables or herbs have been considered as potential chemopreventive
and chemotherapeutic agents due to their non-toxic nature and usage for a long period of time without side effects (4). In preclinical studies, luteolin (3',4',5',7'-tetrahydroxyflavone), a type of flavonoid compound, has been reported to possess various pharmacological properties, including anti-inflammatory, antioxidant and anticancer activities (5-8), with anticancer activity having attracted increased attention in research (9). There is accumulating evidence that luteolin exerts its anti-cancer actions by affecting numerous biochemical pathways, which are critical for the regulation of cell proliferation, cell cycle arrest, apoptosis, angiogenesis, matrix metalloproteinase and metastasis (10-13). Additionally, luteolin has been demonstrated to inhibit the proliferation of leukemia cells and other cells through a mitochondrial-dependent pathway mediated by reactive oxygen species (ROS) (9,14-17). Currently, the effect of luteolin on patients with MDS has not been addressed.

It is recognized that the induction of apoptosis of cancer cells is one of the most important and direct approaches to attenuate the development of cancer and eliminate tumors (18). Increasing evidence from multiple studies has shown that cell apoptosis is closely associated with the loss of mitochondrial inner membrane structure and integrity (9,15). Mitochondria are central to the intrinsic apoptotic pathway, which involves a cascade of molecular events that occur entirely within the cell, and the increased ROS generation that occurs during apoptosis. It is known that ROS are a group of reactive, short-lived, oxygen-containing species, including superoxide, hydrogen peroxide, hydroxyl radicals, singlet oxygen, and peroxy radicals (19). The overgeneration of ROS disrupts the balance between oxidation and antioxidant defense systems and, subsequently, it not only causes oxidative damage to proteins, lipids and nucleic acids, but also leads to the mitochondrial damage including collapse of the mitochondrial membrane potential (ΔΨm) and complex IV inactivation, resulting in mitochondrial dysfunction and consequent induction of cell apoptosis (20). Kittirathphatthana et al (17) reported that luteolin exerts its pro-apoptotic effect partly through generating intracellular ROS, which then contributes to the induction of mitochondria-mediated cell apoptosis. Others have indicated that the overexpression of ROS may contribute to the apoptosis through regulating B-cell lymphoma 2 (Bcl-2) family proteins, releasing cytochrome c from the mitochondria, and activating effector caspases, including caspase-3 and caspase-9 (21). Therefore, a promising strategy for the prevention and treatment of MDS has emerged via inducing apoptosis by mitochondria-mediated ROS generation.

In the present study, SKM-1 cells and primary bone marrow (PBM) mononuclear cells from patients with intermediate- or high-risk MDS were used as models to evaluate the anti-proliferative effect of luteolin on MDS cells. Furthermore, the possible molecular mechanism of luteolin-induced apoptosis in SKM-1 cells was examined, including the p53-dependent mitochondrial signaling pathway mediated by ROS and the expression of apoptosis-related proteins.

Materials and methods

Reagents and culture medium. Luteolin, obtained from Sigma; EMD Millipore (Billerica, MA, USA) was dissolved in dimethylsulfoxide (DMSO) and its concentration adjusted to 100 mM, as stock solutions, for storage at -20°C. This was diluted with medium prior to each experiment, in which the final concentration of DMSO was <0.1%. Fetal bovine serum (FBS) was obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Cell Counting Kit-8 (CCK8) was obtained from Beyotime Institute of Biotechnology (Haimen, China). Annexin V-FITC/PI double staining was obtained from BD Biosciences (Franklin Lakes, NJ, USA). The Fluorometric Protease Assay kit was obtained from Beyotime Institute of Biotechnology. 5,5',6,6'-tetra chloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) Mitochondrial Membrane Potential Assay Kit was obtained from Thermo Fisher Scientific, Inc. 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) and N-acetyl-L-cysteine (NAC) were obtained from Sigma-Aldrich; EMD Millipore. The BCA protein assay kit was obtained from Beijing Biosynthesis Biotechnology Co., Ltd. (Beijing, China). The anti-p53 (cat. no. 2527T), Bcl-2-associated X protein (Bax; cat. no. 5023T), Bcl-2 (cat. no. 2872T), apoptotic protease activating factor 1 (Apaf1; cat. no. 8969T), cytochrome c (cat. no. 11940T), and β-actin (cat. no. 4967S) antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). A secondary HRP-labeled goat anti-rabbit IgG (cat. no. ZB-2301) was obtained from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd. (Beijing, China).

Cell culture. The SKM-1 cell line, originally established from a 76-year-old Japanese male patient with overt monoblastic leukemia following MDS (22), was obtained from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The SKM-1 cells were grown in RPMI-1640 medium containing 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere of 5% CO2 at 37°C, and the cultivating media was replaced every 2 days. SKM-1 cells in logarithmic growth phase were used in all experiments.

Primary cell culture. Between October 2017 and February 2018, PBM cells (>1x10^6/ml) were obtained from the bone marrow of a patient with intermediate MDS (female, 71 years) and two patients with high-risk MDS (male, 75 years; and female, 52 years) in RPMI 1640 medium containing 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere of 5% CO2 at 37°C, and the cultivating media was replaced every 2 days. SKM-1 cells in logarithmic growth phase were used in all experiments.

Cytotoxicity assay. The cells were seeded in triplicate at a density of 5x10^3 cells/well (for SKM-1 cells) or 5x10^5 cells/well (for fresh MDS cells) in 96-well plates, respectively. Following incubation for 24 h, serial dilutions of luteolin (0, 10, 20, 40, 80 and 120 µM) were added and incubated for various durations (12, 24 and 48 and 72 h), following which 10 µl of CCK8 solution (5 g/l) was added to each well and the cells were incubated for another 3 h at 37°C. Subsequently, the optical density for
each well was measured using a Model 550 microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a wavelength of 450 nm according to the manufacturer’s protocol. Cell viability was calculated as the percentage of viable cells in the luteolin-treated group versus the control group. Finally, the obtained cell proliferation plots were used to calculate the half maximal inhibitory concentration (IC50) value of the luteolin.

**Analysis of apoptosis.** To demonstrate the apoptotic features of the cells, the cells treated with or without luteolin were collected, sedimented onto microscopic slides and fixed with methanol. Wright-Giemsa staining (Yeasen Biotech, Shanghai, China) was then performed and images of the apoptotic morphological features were captured using an Olympus IX71 light microscope (Olympus Corporation, Tokyo, Japan). The extent of cell apoptosis was evaluated using Annexin V-FITC/PI double staining as previously reported (23).

**DNA fragmentation assay.** Following treatment with serial dilutions of luteolin for 24 h, the SKM-1 cells were harvested and washed twice with sterile PBS. DNA was collected from the cells using TRizol reagent according to manufacturer’s protocol, and the quality and purity of the isolated DNA were then determined using a UV 2500 spectrophotometer (Shimadzu Corporation, Tokyo, Japan). The DNA samples (15 µg) were then electrophoresed on a 1.5% agarose gel and visualized with ethidium bromide staining under ultraviolet light.

**Measurement of ROS.** Intracellular ROS levels were examined by flow cytometry (FCM) as described previously (24). Briefly, following incubation with serial dilutions of luteolin for 12 h, DCFH-DA working solution was added directly to the culture medium at a final concentration of 10 µM. The cells were then incubated at 37°C for an additional 30 min, following which the cells were collected and the intensity of fluorescence was analyzed by FACSCalibur FCM (BD Biosciences).

**Determination of ΔΨm.** To demonstrate whether luteolin-induced apoptosis is mediated through mitochondrial dysfunction, alterations in ΔΨm were detected by JC-1 staining. Briefly, the SKM-1 cells were pretreated with or without 5 mM NAC for 2 h and then treated with serial dilutions of luteolin for 12 h. The cells (1x10^6 cells/ml) were suspended with PBS and incubated with JC-1 at a final concentration of 2 µM for 20 min at 37°C. The cells were then washed with 1X JC-1 buffer (2 µM) and resuspended in PBS, and illuminated at 488 nm. Images of ΔΨm change from monomer and aggregate were captured using an FV-1000 fluorescence microscope (Olympus Corporation). Fluorescence-activated cell sorting analysis was performed by FCM, and the ratio of JC-1 monomers (green fluorescence) to JC-1 aggregates (orange fluorescence) was calculated for each concentration of luteolin and for the medium control.

**Caspase activity assay.** A Fluorometric Protease Assay kit was used to detect caspase activities according to the manufacturer's protocol. Briefly, the SKM-1 cells were preincubated with or without 5 mM NAC for 2 h and then incubated with serial dilutions of luteolin for 12 h. The cells (2x10^6 cells/ml) were collected and lysed by incubating them with lysis buffer provided in the kit on ice for 10 min. Subsequently, 50 µg of cell lysate proteins in 200 µl of supernatant was incubated with an equal volume of reaction buffer containing fluorogenic peptide substrate at 37°C for 1 h. The fluorescence intensities of cleaved substrate were then determined using a UV 2500 spectrophotometer (Shimadzu Corporation).

**Western blot analysis.** Cell protein extraction and western blot analysis were performed as described previously (25). Briefly, following treatment with luteolin, as described in the DNA fragmentation experiments, the total protein content of the cytosolic fraction in the supernatant was isolated from the harvested cells and measured using a BCA protein assay. The samples (25 µg/lane) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Nonspecific binding sites were blocked with 5% non-fat milk for 1 h. The membranes were then incubated with primary antibodies against p53 (1:1,000), Bax (1:1,000), Bcl-2 (1:1,000), Apaf1 (1:1,000), cytochrome c (1:1,000), and β-actin (1:1,000) for 2 h at 4°C, and then with a secondary HRP-labeled goat anti-mouse IgG (1:2,000) for 1 h at room temperature. The blots were then visualized by enhanced chemiluminescence (ECL system, GE Healthcare Life Sciences, Chalfont, UK) and the density of β-actin served as an internal loading control.

**Statistical analysis.** Data are expressed as the mean ± standard deviation and all analyses were performed with Statistical Package for Social Science (version 18.0; SPSS, Inc., Chicago, IL, USA). Comparisons between two groups were made using Student’s t-test and those between three or more groups were made using one-way analysis of variance followed by the SNK test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Inhibition of cell proliferation following treatment with luteolin.** Following incubation with serial dilutions of luteolin for various durations, the CCK8 assay showed that the proliferation of SKM-1 cells was markedly inhibited in a time- and dose-dependent manner (Fig. 1A) and the dose of luteolin required to yield IC50 was 139.41 µM at 24 h, 39.97 µM at 48 h, and 23.95 µM at 72 h. Notably, the cell viability of PBM mononuclear cells from one patient with intermediate-risk MDS was significantly decreased, compared with that in the medium control group (P<0.05) following treatment with 10, 20, 40, 80 and 120 µM luteolin for 24 and 48 h. Similarly, the cell growth of primary cell cultures from another two patients with high-risk MDS was markedly inhibited, compared with that in the medium control group following treatment with the same concentration of luteolin for 24 and 48 h (all P<0.05; Fig. 1B), although there were no significant differences in cell viability between patients. As luteolin exerted similar antitumor effects on the SKM-1 cells and PBM mononuclear cells from patients with MDS, SKM-1 cells were used as a model to examine the underlying mechanisms of luteolin in the subsequent experiments.
apoptosis in a dose-dependent manner (Fig. 4A-E), suggesting those in the control group, and luteolin induced SKM-1 cell were increased in the luteolin-treated group, compared with luteolin. Apoptotic induction of SKM-1 cells following treatment with the two higher concentrations of luteolin (Fig. 3B). A significant difference was observed between the two groups treated those of 20 µM luteolin, however, no signifi

The effect of luteolin on the extent of cell apoptosis was further quantified by FCM. The apoptotic rates, including cell shrinkage, chromatin condensation and loss of normal nuclear architecture, were observed in the luteolin-treated group under the light microscope, which were not observed in the control group (Fig. 2A and B).

DNA fragmentation analysis following treatment with luteolin. To confirm the induction of apoptosis by luteolin in SKM-1 cells, DNA was isolated and analyzed by agarose gel electrophoresis. As shown in Fig. 3A, a ladder-like pattern of DNA fragmentation became apparent in the SKM-1 cells following treatment with serial dilutions of luteolin for 24 h, whereas no fragments were observed in the medium control group. In particular, a typical ladder pattern of genomic DNA fragmentation was observed in SKM-1 cells exposed to higher concentrations of luteolin (40 and 80 µM), in which the bands were thicker than those of 20 µM luteolin, however, no significant difference was observed between the two groups treated with the two higher concentrations of luteolin (Fig. 3B).

Apoptotic induction of SKM-1 cells following treatment with luteolin. The effect of luteolin on the extent of cell apoptosis was further quantified by FCM. The apoptotic rates, including the sum of cells in early and late apoptosis, for the SKM-1 cells were increased in the luteolin-treated group, compared with those in the control group, and luteolin induced SKM-1 cell apoptosis in a dose-dependent manner (Fig. 4A-E), suggesting that 80 µM luteolin had the largest pro-apoptotic effect on SKM-1 cells. In particular, the apoptotic rates of the SKM-1 cells were increased significantly with the prolonged duration of incubation with 40 µM luteolin (P<0.05; Fig. 4F).

Formation of intracellular ROS following treatment with luteolin. Following treatment with 0, 20, 40 and 80 µM luteolin for 12 h, the mean fluorescence intensity (MFI) for the SKM-1 cells was increased, compared with that in the control group (P<0.05; Fig. 5A). Compared with the corresponding time points for the serial dilutions of luteolin, a significant increase in MFI was observed in the 80 µM luteolin group. In addition, following incubation with 40 µM luteolin for different time intervals, the MFI of the SKM-1 cells was increased significantly with the prolonged duration of incubation (P<0.05; Fig. 5B).

Depolarization of ΔΨm following treatment with luteolin. The cationic dye, JC-1, has the ability to enter into mitochondria and changes in color from green to orange reversibly. In normal cells with high ΔΨm, JC-1 spontaneously aggregates in mitochondria and emits red or orange fluorescence, and in those cells with low ΔΨm, JC-1 remains monomeric and emits green fluorescence. As shown in Fig. 6, the number of SKM-1 cells with orange fluorescence in the control group was higher (Fig. 6A) and the percentage of cells emitting only green fluorescence was increased following exposure of SKM-1 cells to 40 µM luteolin (Fig. 6B). A shift from orange to green emission was observed under the fluorescence microscope, and there were 2.7- and 6.2-fold increases in loss of ΔΨm in response to 20 and 40 µM luteolin, respectively, compared with those in

Figure 1. Effects of luteolin on MDS cell proliferation. (A) Inhibitory rate of SKM-1 cells. Following treatment with serial dilutions of luteolin for various durations, the optical density of SKM-1 cells was measured using a microplate reader. *P<0.05 vs. cells treated with luteolin for 12 h; **P<0.05 vs. cells treated with luteolin for 24 h; *P<0.05 vs. cells treated with luteolin for 48 h. (B) Cell viability of PBM mononuclear cells. Following treatment with serial dilutions of luteolin for either 24 or 48 h, the viability of PBM mononuclear cells from patients with intermediate-risk MDS (Patient 1) or high-risk MDS (Patients 2 and 3) were determined using a Cell Counting Kit-8 assay. Data obtained from three independent experiments are presented as the mean ± standard deviation. If error bars are not present, they are smaller than the thickness of the graph lines. #P<0.05 vs. 10 µM luteolin; &P<0.05 vs. 20 µM luteolin; $P<0.05 vs. 40 µM luteolin; *P<0.05 vs. 80 µM luteolin. MDS, myelodysplastic syndrome; PBM, primary bone marrow.

Figure 2. Morphological features of apoptosis in SKM-1 cells. (A) SKM-1 cells were treated with medium for 24 h as a control group. (B) SKM-1 cells were treated with 20 µM luteolin for 24 h, and observed under a light microscope. A representative image of three independent experiments is shown. The arrow indicates a typical apoptotic cell (Wright-Giemsa staining; magnification, x1,000).
the medium controls (Fig. 7). In particular, preincubation with the antioxidant NAC for 2 h effectively attenuated the loss of ΔΨm caused by luteolin, compared with that in the control group at the same time (P<0.05).
Modulation of caspase activity following treatment with luteolin. Following incubation for 24 h, luteolin markedly induced the activities of caspase-3, -8 and -9 in the SKM-1 cells, and there were significant differences compared with those in either the medium control group or NAC control group (P<0.05). The activities of caspases were higher in the NAC(-)/40 µM luteolin group, compared with those in the NAC(-)/20 µM luteolin group, suggesting that the induction of caspase activity occurred in a dose-dependent manner. Preincubation with the antioxidant NAC for 2 h effectively suppressed the activities of caspase-3, -8 and -9 induced by 40 µM luteolin in the SKM-1 cells (Fig. 8).

Alteration of mitochondrial apoptosis related-proteins following treatment with luteolin. Following incubation with luteolin for 24 h, the increased tumor suppressor protein p53, downregulation of anti-apoptotic protein Bcl-2 and upregulation of pro-apoptotic proteins Bax, Apaf-1, and cytochrome c in the SKM-1 cells were positively associated with the dose of luteolin (Fig. 9A) and there was a significant dose-dependent shift in the ratio of Bax to Bcl-2 (Fig. 9B).

ROS, reactive oxygen species.
Discussion

Cytotoxic chemotherapy is used for patients with MDS with increasing myeloblasts and those who have progressed to acute leukemia. The incidence of MDS has been increasing rapidly with an aging population and an increasing number of individuals exposed to benzene (26). However, the unavailability of a curable approach and the blind strategy choice present challenges for the treatment of MDS. There has been increasing interest in the utilization of natural product-derived compounds as safe and effective chemotherapeutic agents for the treatment of various human diseases due to their diversity of biological activities. As a molecular targeted drug, the anticancer properties of luteolin have been identified to be associated with antiproliferative effects and pro-apoptotic effects, in addition to the inhibition of angiogenesis and metastasis (9,14,27). However, the molecular mechanisms underlying its anticancer activities remain to be fully elucidated.

In the present study, the antiproliferative effect of luteolin on MDS cells was confirmed. The results of a CCK8 assay demonstrated that the proliferation of SKM-1 cells was markedly inhibited, and the dose of luteolin required to yield IC_{50} was 39.97 µM at 48 h, and 23.95 µM at 72 h. Luteolin also markedly inhibited the proliferation of PBMC mononuclear cells from patients with intermediate- or high-risk MDS. Using differentiated enterocytes and the Caco-2 human colon carcinoma cell line, Abdel Hadi et al. (28) demonstrated that luteolin exhibited cytotoxic activity towards human colon cancer cells with minimal or no effect on normal cells. These results suggested that luteolin may be a potential chemopreventive agent with an improved safety profile. In addition, the present study suggested that luteolin suppressed MDS cell proliferation, mainly as a result of the induction of apoptosis, as demonstrated by typical morphological features of cell apoptosis, including cell shrinkage, chromatin condensation and loss of normal nuclear architecture, under the microscope using Wright-Giemsa staining. The formation of DNA fragments of oligonucleosomal size (180-200 bp) is considered to be a hallmark of apoptotic cell death in several cell types (29).

In the present study, the agarose gel electrophoresis showed a typical ladder pattern of genomic DNA fragmentation in the nuclei isolated from SKM-1 cells (Fig. 3). This observation led to the hypothesis that nucleosomal DNA fragmentation may be involved in luteolin-induced apoptosis of MDS cells. In addition, to evaluate the extent of cell apoptosis, Annexin V-FITC/PI double staining was performed; the results of FCM showed additional evidence for the occurrence of apoptosis induced by luteolin in a dose- and time-dependent manner, compared with that in the control group (Fig. 4). Consistent with these results, it has been reported that treatment with luteolin inhibits cell proliferation and induces cell apoptosis in other hematopoietic diseases (14,30-32). Collectively, the results presented in the present study and those of others provide clear evidence that luteolin exhibits cytotoxic effects on cancer cells through the induction of apoptosis, and a luteolin concentration of 80 µM in the present study had the most marked pro-apoptotic effect on the SKM-1 cells.

Apoptosis, the key factor stimulating programmed cell death in cancer cells, has become one of the major mechanisms for the elimination of several types of cancer cell through different pathways, including the mitochondrial pathway (intrinsic pathway), endoplasmic reticulum pathway, or death receptor-mediated apoptotic pathway (extrinsic pathway) (33). These three signaling pathways communicate and interact with one another in physiological conditions, and are important in regulating cell dissolution (34). Accumulating evidence suggests that mitochondria are not only the major source of intracellular ROS, but they are also the major targets of their detrimental effects in mammalian cells (15,35). Luteolin exerts its function as an antioxidant and ROS-generating agent (36), and various contrasting reports have been published regarding the effects of luteolin in the generation of ROS. In previous
studies, Zhang et al. (6) and Shelton et al. (37) reported that luteolin possesses direct and indirect antioxidant effects by scavenging ROS. In agreement, Liu et al. demonstrated that luteolin scavenges ROS generation to protect cells at concentrations of 1.0 and 10 µM (38), whereas others (16,19) reported that luteolin induces ROS accumulation in an early phase via the suppression of cellular superoxide dismutase activity in cancer cells. This discrepancy may be influenced by cell type and the dose of the ROS-inducing agents examined. In the present study, a significant increase in the MFI of SKM-1 cells was detected with the increase in luteolin concentration. Additionally, the MFI of the SKM-1 cells increased significantly with the prolonging of luteolin treatment duration, suggesting that luteolin leads to an intracellular accumulation of ROS in a dose-and time-dependent manner in MDS cells. It is well known that the excessive generation and accumulation of intracellular ROS can cause disruption of ΔΨm, which results in mitochondrial dysfunction and triggers cell apoptosis through multiple downstream signaling pathways (39). Similarly, Choi et al. reported that a decrease in ΔΨm following intense ROS generation induced mitochondrial disruption, inhibition of mitochondrial respiratory chain, reduction of ATP synthesis, and cell death (40). In the present study, the Annexin V-FITC/PI double staining and JC-1 staining showed that the dose of luteolin used in the experiments resulted in SKM-1 cell apoptosis, and this event was preceded by sustained hyperpolarization of the mitochondrial membrane, as demonstrated by the results of FCM and fluorescent microscope. A shift from orange to green emission was observed under the fluorescence microscope, and there was a higher fold increase in loss of ΔΨm in response to the increase of luteolin concentration, compared with that in the control group. Preincubation with the antioxidant NAC effectively attenuated the loss of ΔΨm caused by luteolin, compared with that in the control group at the same time. The results of these experiments indicated that luteolin inhibited cell proliferation and induced cell apoptosis through the mitochondrial pathway, mediated by ROS, in MDS cells.

P53, a tumor suppressor protein, is involved in inducing cell apoptosis (41). There is increasing evidence that luteolin activates the intrinsic apoptosis pathway through inducing DNA damage and activating the marked p53-dependent inhibition of cell proliferation and cell apoptosis in several cancer cell lines, including EC1 and KYSE450 esophageal carcinoma cells (9), HepG2 cells (42), cervical cancer cells (43), HT-29 colon cancer cells (44) and human RPE cells (45). Several lines of evidence have demonstrated that overexpression of the p53 gene suppresses the growth of human tumor cell lines (46,47). The results of the present study confirmed that, following incubation with luteolin for 24 h, the protein expression of p53 was augmented with the increasing concentration of luteolin. Therefore, these findings and those of others indicate that the p53 protein may act as a major activator for the induction of apoptosis in luteolin-treated SKM-1 cells. Until now, the mechanisms by which p53 regulates cell apoptosis have not been well illustrated, however, Bcl-2 family proteins, which comprise pro-apoptotic and anti-apoptotic members, are important in p53-dependent apoptosis (41). It has been shown that p53 directly activates the transcription of several genes encoding members of the Bcl-2 family, which can positively or negatively regulate mitochondrial outer membrane permeabilization to promote the release of cytochrome c and other apoptotic molecules (48). To further examine the underlying mechanisms of p53-mediated apoptosis in luteolin-treated SKM-1 cells, the protein expression levels of Bax and Bcl-2 were determined by western blot analysis in the present study. The results confirmed that the mechanisms of luteolin-induced cell apoptosis may involve the downregulation of Bcl-2 and upregulation of Bax proteins in a dose-dependent manner, leading to a significant dose-dependent shift in the ratio of Bax to Bcl-2 family proteins in favor of the activation of caspase-3 in MDS cells. These findings are consistent with the findings of other studies that luteolin can activate the protein levels of Bax and Bcl-2 in human osteosarcoma, lung adenocarcinoma and glioblastoma cells (39,49,50). Collectively, these findings suggested that luteolin induces cell apoptosis via the p53-dependent mitochondrial signaling pathway by modulating a number of target proteins, particularly Bcl-2 and Bax.

It is known that the induction of apoptosis is accompanied by the release of cytochrome c from mitochondria, which is considered one of the most important pro-apoptotic proteins and key in the assembly of a multimolecular complex known as the apoptosome. Its levels are markedly reduced in the normal cell cytoplasm and markedly increased in apoptotic cells (51). The increased generation of ROS induces the release of cytochrome c from mitochondria to the cytoplasm (17), where it binds Apaf-1. The subsequent exchange of ADP/dADP for ATP/dATP in Apaf-1 triggers it to form an apoptosome (52). Therefore, the expression of cytochrome c was analyzed in the present study to examine whether cytochrome c had been released from the mitochondrial membrane in MDS cells, and to determine how cytochrome c activates the downstream effector caspases to induce apoptosis in SKM-1 cells following incubation with luteolin. The results indicated that the levels of cytochrome c increased significantly with the processing of caspase in a dose-dependent manner, compared with those in the control group. In addition, following incubation with luteolin for 24 h, the accumulation of ROS appeared to upregulate the proapoptotic protein Apaf-1 in SKM-1 cells. Luteolin has been found to increase the expression of Bax and caspase-3 and decrease the expression of Bcl-2 in liver carcinoma cells, but exerted almost no effects on normal liver HL-7702 cells (53). Therefore, it is reasonable to suggest that luteolin-induced ROS generation may be an early event in MDS cells, which promotes the induction of cell apoptosis by the release of cytochrome c from mitochondria.

Caspases are another important family of proteins involved in the downstream events of p53-mediated apoptosis (41). Caspase-3, an aspartic acid-specific cysteine protease, is the most widely studied mammalian caspase, which activates as cleaved caspase-3 by specific shearing off the inactive subunit in the location of aspartic acid. Additionally, it is important in both death pathways, and cleaves a wide range of cellular substrates (54). To elucidate whether caspase activation was involved in luteolin-induced apoptosis, a fluorometric assay was performed to detect the activities of caspase-3, -8, and -9. Following incubation for 24 h, luteolin significantly induced the activation of caspase-3, -8 and -9 in SKM-1 cells in a
dose-dependent manner. Preincubation with the antioxidant NAC for 2 h effectively suppressed the activity of caspase-3, -8 and -9 induced by 40 µM luteolin (Fig. 8). These results supported the hypothesis that luteolin induces ROS-mediated apoptosis by activating caspase-dependent pathways.

In conclusion, luteolin was shown to inhibit the proliferation of SKM-1 cells and exerted its pro-apoptotic action partly through the p53-dependent mitochondrial signaling pathway mediated by intracellular ROS. This provides a promising therapeutic candidate for patients with MDS. However, further investigation of luteolin in clinical trials is required to confirm these results.

Acknowledgements

The authors would like to thank Dr Feng Gao for technical assistance.

Funding

This study was supported by the Fund for Young Scholars in Jiangsu Province (grant no. BK 20150253), the Fund of Science and Technology Bureau of Changzhou, Jiangsu, China (grant no. CJ20150418) and the Changzhou High-Level Medical Talents Training Project (grant no. 20162CLJ024).

Availability of data and materials

All datasets generated and analysed in the present study are included in this published article.

Authors' contributions

WD and WG conceived and designed the study. YaL, YC and YuL performed all the experiments. XX performed all the clinical diagnoses and treatments. YaL and YC analyzed the data. WD and YaL wrote the manuscript. WG revised the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

All patients involved in the present study provided the written informed consent and the Institutional Review Board of The Third Affiliated Hospital of Soochow University approved the study.

Consent for publication

All the study participants provided consent for the data to be published.

Competing interests

The authors declare that they have no competing interests.

References


17. Kittiratphathana N, Kukongviriyapan V, Prawan A and Kittiratphatthana NAc for 2 h effectively suppressed the activity of caspase-3, -8 and -9 induced by 40 µM luteolin (Fig. 8). These results supported the hypothesis that luteolin induces ROS-mediated apoptosis by activating caspase-dependent pathways.

In conclusion, luteolin was shown to inhibit the proliferation of SKM-1 cells and exerted its pro-apoptotic action partly through the p53-dependent mitochondrial signaling pathway mediated by intracellular ROS. This provides a promising therapeutic candidate for patients with MDS. However, further investigation of luteolin in clinical trials is required to confirm these results.

Acknowledgements

The authors would like to thank Dr Feng Gao for technical assistance.

Funding

This study was supported by the Fund for Young Scholars in Jiangsu Province (grant no. BK 20150253), the Fund of Science and Technology Bureau of Changzhou, Jiangsu, China (grant no. CJ20150418) and the Changzhou High-Level Medical Talents Training Project (grant no. 20162CLJ024).

Availability of data and materials

All datasets generated and analysed in the present study are included in this published article.

Authors' contributions

WD and WG conceived and designed the study. YaL, YC and YuL performed all the experiments. XX performed all the clinical diagnoses and treatments. YaL and YC analyzed the data. WD and YaL wrote the manuscript. WG revised the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

All patients involved in the present study provided the written informed consent and the Institutional Review Board of The Third Affiliated Hospital of Soochow University approved the study.

Consent for publication

All the study participants provided consent for the data to be published.

Competing interests

The authors declare that they have no competing interests.

References


